Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Credit agrmnt [a]
Appointed director
Kadmon Holdings, Inc. (KDMN) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2022 SC 13G/A Point72 Asset Management, L.P. reports a 0% stake in Kadmon Holdings, Inc.
11/19/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
11/16/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/16/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/09/2021 4 Waksal Harlan (President, CEO) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 177,945 shares @ $9.5, valued at $1.7M
Disposed/sold 655,000 rights @ $3.64, valued at $2.4M
Disposed/sold 982,500 options to buy @ $4.06, valued at $4M
Disposed/sold 1,350,000 options to buy @ $4.15, valued at $5.6M
Disposed/sold 2,000,000 options to buy @ $3.96, valued at $7.9M
Disposed/sold 750 options to buy @ $6, valued at $4.5k
11/09/2021 4 Flowers Cynthia Louise (Director) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Gifted 20,150 shares @ $0
Disposed/sold 10,850 shares @ $9.5, valued at $103.1k
Disposed/sold 64,935 options to buy @ $2.27, valued at $147.4k
Disposed/sold 100,000 options to buy @ $2.29, valued at $229k
Disposed/sold 85,034 options to buy @ $4.44, valued at $377.6k
Disposed/sold 96,975 options to buy @ $3.58, valued at $347.2k
11/09/2021 4 Ryan John L (EVP, Chief Medical Officer) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 100,000 options to buy @ $4.66, valued at $466k
Disposed/sold 150,000 options to buy @ $3.64, valued at $546k
Disposed/sold 50,000 options to buy @ $2.47, valued at $123.5k
Disposed/sold 100,000 options to buy @ $4.34, valued at $434k
Disposed/sold 175,000 options to buy @ $3.96, valued at $693k
Disposed/sold 250 options to buy @ $6, valued at $1.5k
11/09/2021 4 Kirsch Arthur S (Director) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 30,000 shares @ $9.5, valued at $285k
Disposed/sold 64,103 options to buy @ $2.29, valued at $146.8k
Disposed/sold 100,000 options to buy @ $2.29, valued at $229k
Disposed/sold 85,034 options to buy @ $4.44, valued at $377.6k
Disposed/sold 96,975 options to buy @ $3.58, valued at $347.2k
11/09/2021 4 Moss Gregory S. (EVP, Gen. Coun. / CCO.) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 17,671 shares @ $9.5, valued at $167.9k
Disposed/sold 75,000 rights @ $4.66, valued at $349.5k
Disposed/sold 150,000 options to buy @ $3.64, valued at $546k
Disposed/sold 75,000 options to buy @ $2.47, valued at $185.3k
Disposed/sold 300,000 options to buy @ $2.14, valued at $642k
Disposed/sold 360,000 options to buy @ $4.34, valued at $1.6M
Disposed/sold 680,000 options to buy @ $3.96, valued at $2.7M
Disposed/sold 200 options to buy @ $6, valued at $1.2k
11/09/2021 4 Miller-Rich Nancy (Director) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 36,364 options to buy @ $4.17, valued at $151.6k
Disposed/sold 96,975 options to buy @ $3.58, valued at $347.2k
11/09/2021 4 Meehan Steven (EVP, CFO) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 24,909 shares @ $9.5, valued at $236.6k
Disposed/sold 25,000 options to buy @ $4.12, valued at $103k
Disposed/sold 25,000 options to buy @ $3.35, valued at $83.8k
Disposed/sold 400,000 options to buy @ $2.17, valued at $868k
Disposed/sold 500,000 options to buy @ $4.34, valued at $2.2M
Disposed/sold 1,020,000 options to buy @ $3.96, valued at $4M
11/09/2021 4 Cohen David E (Director) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 64,935 options to buy @ $2.27, valued at $147.4k
Disposed/sold 100,000 options to buy @ $2.29, valued at $229k
Disposed/sold 85,034 options to buy @ $4.44, valued at $377.6k
Disposed/sold 96,975 options to buy @ $3.58, valued at $347.2k
11/09/2021 4 Konidaris Tasos (Director) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 50,000 options to buy @ $4.12, valued at $206k
Disposed/sold 50,000 options to buy @ $3.35, valued at $167.5k
Disposed/sold 100,000 options to buy @ $2.29, valued at $229k
Disposed/sold 102,040 options to buy @ $4.44, valued at $453.1k
Disposed/sold 116,370 options to buy @ $3.58, valued at $416.6k
11/09/2021 4 Carver Kyle (SVP, CAO, Controller) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 15,420 shares @ $9.5, valued at $146.5k
Disposed/sold 45,000 options to buy @ $4.66, valued at $209.7k
Disposed/sold 55,000 options to buy @ $3.64, valued at $200.2k
Disposed/sold 50,000 options to buy @ $2.47, valued at $123.5k
Disposed/sold 100,000 options to buy @ $4.34, valued at $434k
Disposed/sold 175,000 options to buy @ $3.96, valued at $693k
11/09/2021 4 Bauer Eugene (Director) has filed a Form 4 on Kadmon Holdings, Inc.
Txns: Disposed/sold 1,716 shares @ $9.5, valued at $16.3k
Disposed/sold 5,000 shares @ $9.5, valued at $47.5k
Disposed/sold 3,077 options to buy @ $4.66, valued at $14.3k
Disposed/sold 25,000 options to buy @ $4.12, valued at $103k
Disposed/sold 25,000 options to buy @ $3.35, valued at $83.8k
Disposed/sold 100,000 options to buy @ $2.29, valued at $229k
Disposed/sold 85,034 options to buy @ $4.44, valued at $377.6k
Disposed/sold 96,975 options to buy @ $3.58, valued at $347.2k
11/09/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accele...
Docs: "Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company",
"First Supplemental Indenture, by and between Kadmon Holdings, Inc. and U.S. Bank National Association, as Trustee",
"Paris – November 9, 2021 - Sanofi announced today the completion of its acquisition of Kadmon Holdings, Inc. The acquisition further strengthens growth and expansion for the"
11/09/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/09/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/09/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
11/09/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
11/05/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/04/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/04/2021 8-K Quarterly results
Docs: "REZUROCK™ · On August 19, 2021 REZUROCK became commercially available for shipment to prescribed patients in the United States through a network of rare hematology/oncology specialty pharmacies and distributors o Execution of commercial launch remain underway, with a focus on generating awareness of REZUROCK's differentiated clinical value and facilitating market access o Experienced field team call on all target accounts, including engagement with 100% of the top 80 transplant centers, where ~90% of chronic graft-versus-host disease patients in the U.S. are treated o Strong sales performance and demand during initial launch period; $12.2 million net sales achieved in 3Q 2021 o The Company plans to present data on belumosudil at the 63rd American Society of Hematology Annual Me..."
10/27/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/27/2021 8-K Other Events  Interactive Data
10/21/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/21/2021 8-K Other Events  Interactive Data
10/04/2021 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
09/21/2021 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
09/17/2021 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
09/08/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/08/2021 8-K Quarterly results
08/05/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/05/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy